## Ludwig Wagner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10481387/publications.pdf

Version: 2024-02-01

331538 206029 2,531 77 21 48 citations h-index g-index papers 82 82 82 3412 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Critical Care, 2013, 17, R25.	2.5	969
2	Cloning and Expression of Secretagogin, a Novel Neuroendocrine- and Pancreatic Islet of Langerhans-specific Ca2+-binding Protein. Journal of Biological Chemistry, 2000, 275, 24740-24751.	1.6	150
3	Binding of calcium ions and SNAP-25 to the hexa EF-hand protein secretagogin. Biochemical Journal, 2007, 401, 353-363.	1.7	88
4	Monocyte Chemoattractant Protein (MCP)-4 Expression in the Airways of Patients with Asthma. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 723-732.	2.5	79
5	A secretagogin locus of the mammalian hypothalamus controls stress hormone release. EMBO Journal, 2015, 34, 36-54.	3 <b>.</b> 5	75
6	Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients. Cancer Investigation, 2012, 30, 615-621.	0.6	60
7	The ATP-dependent helicase RUVBL1/TIP49a associates with tubulin during mitosis. Cytoskeleton, 2003, 56, 79-93.	4.4	59
8	Expression of TAU in insulin-secreting cells and its interaction with the calcium-binding protein secretagogin. Journal of Endocrinology, 2010, 205, 25-36.	1.2	52
9	A <scp>TRPV</scp> 1â€toâ€secretagogin regulatory axis controls pancreatic βâ€cell survival by modulating protein turnover. EMBO Journal, 2017, 36, 2107-2125.	3 <b>.</b> 5	52
10	Secretagogin Is a Novel Marker for Neuroendocrine Differentiation. Neuroendocrinology, 2005, 82, 121-138.	1.2	50
11	Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurgical Review, 2013, 36, 45-56.	1.2	48
12	Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method. Scientific Reports, 2019, 9, 13783.	1.6	41
13	Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma. Tumor Biology, 2016, 37, 1173-1182.	0.8	39
14	Identification of a high-affinity network of secretagogin-binding proteins involved in vesicle secretion. Molecular BioSystems, 2011, 7, 2196.	2.9	35
15	Secretagogin is Expressed in Sensory CGRP Neurons and in Spinal Cord of Mouse and Complements other Calcium-Binding Proteins, with a Note on Rat and Human. Molecular Pain, 2012, 8, 1744-8069-8-80.	1.0	34
16	NephroCheck data compared to serum creatinine in various clinical settings. BMC Nephrology, 2015, 16, 206.	0.8	33
17	Levamisole induced apoptosis in cultured vascular endothelial cells. British Journal of Pharmacology, 2000, 131, 1577-1583.	2.7	32
18	Prevalence of Strongyloides stercoralis infection and hyperinfection syndrome among renal allograft recipients in Central Europe. Scientific Reports, 2018, 8, 15406.	1.6	30

#	Article	IF	CITATIONS
19	Secretagogin-dependent matrix metalloprotease-2 release from neurons regulates neuroblast migration. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E2006-E2015.	3.3	27
20	The Microtubule-Associated Protein Tau and Its Relevance for Pancreatic Beta Cells. Journal of Diabetes Research, 2016, 2016, 1-12.	1.0	26
21	Localization and characterization of the novel protein encoded by C20orf3. Biochemical Journal, 2008, 414, 485-495.	1.7	25
22	Novel Insights into the Distribution and Functional Aspects of the Calcium Binding Protein Secretagogin from Studies on Rat Brain and Primary Neuronal Cell Culture. Frontiers in Molecular Neuroscience, 2012, 5, 84.	1.4	25
23	Immunoreactivity of calcium binding protein secretagogin in the human hippocampus is restricted to pyramidal neurons. Experimental Gerontology, 2007, 42, 215-222.	1.2	23
24	Secretagogin is a new neuroendocrine marker in the human prostate. Prostate, 2007, 67, 472-484.	1.2	22
25	20 Years of Secretagogin: Exocytosis and Beyond. Frontiers in Molecular Neuroscience, 2019, 12, 29.	1.4	21
26	Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice. Journal of Neural Transmission, 2011, 118, 737-745.	1.4	19
27	Blood Alterations Preceding Clinical Manifestation of Glioblastoma. Cancer Investigation, 2012, 30, 625-629.	0.6	19
28	Long-Term in vitro Growth of Human Insulin-Secreting Insulinoma Cells. Neuroendocrinology, 2006, 83, 123-130.	1.2	17
29	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. ESMO Open, 2020, 5, e000863.	2.0	17
30	Angiogenic factors in plasma of brain tumour patients. Anticancer Research, 2009, 29, 731-6.	0.5	17
31	Detection of BLT substrate-specific proteases in individual human peripheral blood leucocytes and bone marrow cells. Journal of Immunological Methods, 1991, 142, 147-155.	0.6	16
32	Setagin and secretagogin-R22: Posttranscriptional modification products of the secretagogin gene. Biochemical and Biophysical Research Communications, 2005, 329, 1193-1199.	1.0	16
33	Elevated blood markers 1 year before manifestation of malignant glioma. Neuro-Oncology, 2010, 12, 1004-1008.	0.6	16
34	Expression of secretagogin in clear-cell renal cell carcinomas is associated with a high metastasis rate. Human Pathology, 2011, 42, 641-648.	1.1	16
35	Circulating biomarkers of CNS tumors: an update. Biomarkers in Medicine, 2013, 7, 267-285.	0.6	16
36	Brain natriuretic peptide correlates with the extent of atrial fibrillation-associated silent brain lesions. Clinical Biochemistry, 2008, 41, 1434-1439.	0.8	15

#	Article	IF	CITATIONS
37	Color-Contrast Staining of Two Different Lymphocyte Subpopulations: A Two-Color Modification of Alkaline Phosphatase Monoclonal Anti-Alkaline Phosphatase Complex Technique. Biotechnic & Histochemistry, 1988, 63, 129-136.	0.4	14
38	Upregulation of a lymphoid serine protease in kidney allograft recipients. Kidney International, 1990, 37, 1350-1356.	2.6	14
39	Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. Journal of Neuro-Oncology, 2013, 112, 347-354.	1.4	14
40	Urinary neprilysin in the critically ill patient. BMC Nephrology, 2017, 18, 172.	0.8	14
41	Secretagogin expression in the vertebrate brainstem with focus on the noradrenergic system and implications for Alzheimer's disease. Brain Structure and Function, 2019, 224, 2061-2078.	1.2	14
42	Hypoalbuminemia as predictor of recurrence of Clostridium difficile infection. Wiener Klinische Wochenschrift, 2019, 131, 68-74.	1.0	14
43	Opposite effects of serum- and glucocorticoid-regulated kinase-1 and glucocorticoids on POMC transcription and ACTH release. American Journal of Physiology - Endocrinology and Metabolism, 2011, 301, E336-E341.	1.8	13
44	The role of proto-oncogene GLI1 in pituitary adenoma formation and cell survival regulation. Endocrine-Related Cancer, 2015, 22, 793-803.	1.6	13
45	Brain-wide genetic mapping identifies the indusium griseum as a prenatal target of pharmacologically unrelated psychostimulants. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 25958-25967.	3.3	12
46	The urinary microbiome shows different bacterial genera in renal transplant recipients and non-transplant patients at time of acute kidney injury – a pilot study. BMC Nephrology, 2020, 21, 117.	0.8	11
47	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. Cancer Immunology, Immunotherapy, 2021, 70, 3643-3650.	2.0	10
48	CXC Chemokine Ligand 12 Protects Pancreatic $\hat{l}^2$ -Cells from Necrosis through Akt Kinase-Mediated Modulation of Poly(ADP-ribose) Polymerase-1 Activity. PLoS ONE, 2014, 9, e101172.	1.1	10
49	CXCL12/SDF-1 over-expression in human insulinomas and its biological relevance. Molecular and Cellular Endocrinology, 2009, 298, 1-10.	1.6	8
50	High plasma-GFAP levels in metastatic myxopapillary ependymoma. Journal of Neuro-Oncology, 2013, 113, 359-363.	1.4	8
51	Secretagogin expression in tumours of the human brain and its coverings. Apmis, 2007, 115, 319-326.	0.9	7
52	Inhibition of cytotoxic T-lymphocyte-triggered apoptosis by target cell surface-coupled aprotinin. Molecular Immunology, 1995, 32, 853-864.	1.0	6
53	Antibody Response against the SARS-CoV-2 Nucleocapsid Protein and Its Subdomainsâ€"Identification of Pre-Immunization Status by Human Coronaviruses with Multipanel Nucleocapsid Fragment Immunoblotting. Covid, 2021, 1, 105-114.	0.7	6
54	Protein Networks Involved in Vesicle Fusion, Transport, and Storage Revealed by Array-Based Proteomics. Methods in Molecular Biology, 2011, 781, 47-58.	0.4	6

#	Article	IF	CITATIONS
55	The urine biomarker panel [IGFBP7]x[TIMP-2] (NephroCheck® parameter) does not correlate with IGFBP7 and TIMP-2 gene expression in urinary sediment. PLoS ONE, 2017, 12, e0188316.	1.1	6
56	Inadvertent Catheter-Induced Right Bundle Branch Block in a Patient with Preexistent Left Bundle Branch Block and Recurrent Macroreentrant Ventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1989, 12, 1857-1862.	0.5	5
57	COVID-19 serology in nephrology healthcare workers. Wiener Klinische Wochenschrift, 2021, 133, 923-930.	1.0	5
58	DDRGK1 in urine indicative of tubular cell injury in intensive care patients with serious infections. Journal of Nephropathology, 2016, 5, 65-71.	0.1	5
59	Interferon alphaâ€2 for hairy cell leukemia: Evidence for induction of RNA synthesis in hairy cells and failure to correlate enhancement of natural killer cells with elimination of hairy cells. European Journal of Haematology, 1987, 39, 418-425.	1.1	4
60	Urinary nephrospheres indicate recovery from acute kidney injury in renal allograft recipients – a pilot study. BMC Nephrology, 2019, 20, 251.	0.8	4
61	Age related changes in pancreatic beta cells: A putative extra-cerebral site of Alzheimer's pathology. World Journal of Diabetes, 2011, 2, 49.	1.3	4
62	Urinary C3 levels associated with sepsis and acute kidney injuryâ€"A pilot study. PLoS ONE, 2021, 16, e0259777.	1.1	4
63	Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including Omicron. Viruses, 2022, 14, 1181.	1.5	4
64	Plasma PD-L1 concentration in patients with brain metastases from solid tumors Journal of Clinical Oncology, 2015, 33, e13026-e13026.	0.8	3
65	Renal Expression of Light Chain Binding Proteins. Frontiers in Medicine, 2020, 7, 609582.	1.2	2
66	Structural analysis of urinary light chains and proteomic analysis of hyaline tubular casts in light chain associated kidney disorders. PeerJ, 2019, 7, e7819.	0.9	2
67	A novel approach to immunoapheresis of C3a/C3 and proteomic identification of associates. PeerJ, 2019, 7, e8218.	0.9	2
68	Preclinical Establishment of a Divalent Vaccine against SARS-CoV-2. Vaccines, 2022, 10, 516.	2.1	2
69	Incidence and phenotype restriction of lymphoid BLT-serine protease granules in spontaneously diabetes prone BB rats compared with a normal rat strain. Journal of Autoimmunity, 1992, 5, 581-590.	3.0	1
70	Cytomegalovirus in urinary sediment in patients with acute kidney injury. BMC Nephrology, 2021, 22, 169.	0.8	1
71	Correlation of plasma PD-L1 detectability with age in glioma patients Journal of Clinical Oncology, 2015, 33, e13039-e13039.	0.8	1
72	Heparin-binding protein as a novel biomarker for sepsis-related acute kidney injury. PeerJ, 2020, 8, e10122.	0.9	1

#	Article	IF	CITATIONS
73	FP239NEPHROSPHERE-LIKE STRUCTURES IN URINE OF ALLOTRANSPLANT RECIPIENTS FOLLOWING ACUTE KIDNEY INJURY. Nephrology Dialysis Transplantation, 2018, 33, i109-i109.	0.4	0
74	FP247The urinary microbiome during acute kidney injury in renal transplant recipients versus non-transplant recipients. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
75	PO116DISCOVERY OF A NOVEL ANTIMICROBIAL COMPOUND AGAINST PSEUDOMONAS AERUGINOSA FROM URINE OF KTX PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	O
76	SUN-639 Secretagogin Levels Are Unrelated to Gestational Diabetes Mellitus in a Cohort of Pregnant Women. Journal of the Endocrine Society, 2020, 4, .	0.1	0
77	Characterization of candidate tissue and blood biomarkers in a rare cohort of myxopapillary ependymoma patients Journal of Clinical Oncology, 2013, 31, 2040-2040.	0.8	0